CAS: 535935-84-3; 6,7-Dihydro-5H-Cyclopenta[b]Pyridin-5-Amine
该化合物是一种环环环有机化合物,其特点是双环结构,包括环球环的环状环,该化合物具有一种矿物质功能组,有助于其潜在的反应和生物活动;环和矿群中氮原子的存在可影响其溶性,极度和与生物目标的相互作用;一般而言,这种性质的化合物可能具有药理特性,使其对医药化学感兴趣;分子结构允许采用各种替代模式,从而进一步改变其化学行为和生物活动;此外,该化合物在药物开发或作为化学中间体的稳定性,再活性和潜在应用可能受到其特定的电子和化学特性的影响.
- 英文名称6,7-Dihydro-5H-Cyclopenta[b]Pyridin-5-Amine
- 中文名称6,7-二氢-5H-环戊二烯[b]吡啶-5-胺
- IUPAC名称6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine
- 其它别名6,7-二氢-5H-2,3-环戊烯并吡啶-5-胺; 6,7-Dihydro-5H-Cyclopenta[beta]Pyridin-5-Amine
- CAS编号535935-84-3
- MFCD编号:MFCD07371658
- 分子式:C8H10N2分子量:134.18
- 产品CID: 1519564
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
1187930-17-1 2765452-27-3 2739982-66-0物理性质
MSDS等安全信息
上下游产品
CAS号1071727-80-4 6,7-dihydro-[1]...合成工艺路线路线简述
📜6,7-Dihydro-[1]Pyrindin-5-One O-Methyl-Oxime置于钯体系中,用 三氟乙酸 作为反应溶剂,化学反应 14.0H,反应生成 6,7-二氢-5H-环戊并[b]吡啶-5-胺
参考文献:Substituted Fluoroethyl Ureas As Alpha 2 Adrenergic Agents
标题:Substituted Fluoroethyl Ureas As Alpha 2 Adrenergic Agents
摘要:本文披露了治疗化合物,以及与之相关的方法,组合物和药物.
海关参考信息
- 2933310010-吡啶
2939800000-其他生物碱 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7094909-B2
优先权日:2001-06-11
标 题 :HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
发明人：KUCERA DAVID JOHN; SCOTT ROBERT WILLIAM
权利人:AGOURON PHARMA
摘要:The present invention concerns processes for preparing compounds of formula (I-H), or a prodrug, pharmaceutically active metabolite, or pharmaceutically active salt or solvate thereof, n nwhich are useful as inhibitors of the HIV protease enzyme.
专利号:US-9428490-B2
优先权日:2011-07-29
标 题 :Nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
